Novel method for reducing plasma cholesterol: a ligand replacement therapy.
Despite wide use of statins, significant cardiovascular disease risk persists. High-density lipoprotein based therapy has not yielded any positive results in combating this disease. Newer methods to rapidly decrease plasma cholesterol are much needed. While apolipoprotein B is a ligand for low-density lipoprotein receptor, which clears low-density lipoprotein cholesterol in a highly regulated pathway, apolipoprotein E (apoE) is a ligand for clearing other apolipoprotein B containing atherogenic lipoproteins via an alternate receptor pathway, especially the heparin sulfate proteoglycans on the liver cell surface. We describe here a novel method that replaces apoE as a ligand to clear all of the atherogenic lipoproteins via the heparin sulfate proteoglycans pathway. This ligand replacement apoE mimetic peptide therapy, having been designated as an orphan drug by the US FDA, is in clinical trials.
Department of Medicine, Biochemistry & Molecular Genetics; University of Alabama at Birmingham, Birmingham, AL 35294, USA.
G M
GM
Anantharamaiah
LipimetiX Development, LLC, Natick, MA 01760, USA.
Dennis
D
Goldberg
CVD; HDL; HMG-CoA; HSPG; LDL-cholesterol; LDL-receptor; PCSK-9; SREBP; VLDL; alternate pathway for cholesterol clearance; apoB; apoB-containing lipoproteins; apoE mimetic; ligand replacement therapy; monoclonal antibodies